Literature DB >> 29161357

Nivolumab in non-small-cell lung cancer with EGFR mutation.

H Yoshida1, Y H Kim2, H Ozasa1, H Nagai1, Y Sakamori1, T Tsuji1, T Nomizo1, Y Yasuda1, T Funazo1, T Hirai1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29161357     DOI： 10.1093/annonc/mdx745

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  17 in total

1.  B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.

Authors:  Youwei Lu; Fengying Wu; Qiuyi Cao; Yu Sun; Moli Huang; Jing Xiao; Bin Zhou; Liang Zhang
Journal:  Oncogene       Date:  2021-11-27       Impact factor: 9.867

Review 2.  Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer.

Authors:  Dehua Liao; Lun Yu; Dangang Shangguan; Yongchang Zhang; Bowen Xiao; Ni Liu; Nong Yang
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

3.  Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.

Authors:  Xiaoyang Zhai; Xuquan Jing; Ji Li; Yaru Tian; Shuhui Xu; Min Wang; Hui Zhu
Journal:  Front Oncol       Date:  2020-09-30       Impact factor: 6.244

4.  Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Giorgia Guaitoli; Marcello Tiseo; Massimo Di Maio; Luc Friboulet; Francesco Facchinetti
Journal:  Transl Lung Cancer Res       Date:  2021-06

5.  Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.

Authors:  Tadaaki Yamada; Soichi Hirai; Yuki Katayama; Akihiro Yoshimura; Shinsuke Shiotsu; Satoshi Watanabe; Toshiaki Kikuchi; Kazuki Hirose; Yutaka Kubota; Yusuke Chihara; Taishi Harada; Keiko Tanimura; Takayuki Takeda; Nobuyo Tamiya; Yoshiko Kaneko; Junji Uchino; Koichi Takayama
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

6.  Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report.

Authors:  Yuri Taniguchi; Momoko Yamamoto; Hiroaki Ikushima; Sayaka Ohara; Hideyuki Takeshima; Toshio Sakatani; Kazuhiro Usui
Journal:  Case Rep Oncol       Date:  2019-07-16

Review 7.  Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

Authors:  Peter T Harrison; Simon Vyse; Paul H Huang
Journal:  Semin Cancer Biol       Date:  2019-09-25       Impact factor: 15.707

8.  A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.

Authors:  Hiromi Watanabe; Kadoaki Ohashi; Kazuya Nishii; Keisuke Seike; Go Makimoto; Katsuyuki Hotta; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Intern Med       Date:  2019-07-10       Impact factor: 1.271

Review 9.  Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.

Authors:  Anqi Lin; Ting Wei; Hui Meng; Peng Luo; Jian Zhang
Journal:  Mol Cancer       Date:  2019-09-16       Impact factor: 27.401

10.  Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.

Authors:  Zhenzhen Fan; Yahui Tian; Zhipeng Chen; Lu Liu; Qian Zhou; Jingjing He; James Coleman; Changjiang Dong; Nan Li; Junqi Huang; Chenqi Xu; Zhimin Zhang; Song Gao; Penghui Zhou; Ke Ding; Liang Chen
Journal:  EMBO Mol Med       Date:  2020-05-11       Impact factor: 12.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.